Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416946585> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2416946585 endingPage "5" @default.
- W2416946585 startingPage "991" @default.
- W2416946585 abstract "Thirty-seven patients (pts) with previously untreated and measurable advanced soft tissue sarcoma entered this phase II study: 22 men and 15 women were included. Median age was 58 (range: 20-71). The starting dose of epirubicin was 100 mg/m2 IV bolus every 3 wks. In the case of minimal myelosuppression, the dose was increased by 10 mg/m2 to 130 mg/m2 (Mean dose per cycle: 105 mg/m2). Median cumulative dose of epirubicin administered was 445 mg/m2 (range: 200-1320 mg/m2). From 32 evaluable pts, one had a complete response (CR), 5 a partial response (PR), (CR + PR = 18.7% +/- 13.8%), 12 showed no change (37.5%) and 14 had progressive disease. The number of complete or partial responses observed was not modified by increasing the doses of epirubicin. Median time to progression was 4 months. From 32 pts evaluable for toxicity, hematologic toxicity at d 21 was mild. Non hematological toxicities consisted of nausea and vomiting in 74% of pts (WHO grade 3 = 5%), stomatitis in 12.2% (WHO grade 3 = 3%) and alopecia in 91% (WHO grade 2-3 = 72%). No cardiac dysfunction was recorded during the treatment, even though 7 patients received more than 800 mg/m2 of epirubicin (median: 850 mg/m2, range: 810-1320 mg/m2). The results of this study show that epirubicin is an active drug in advanced soft tissue sarcoma." @default.
- W2416946585 created "2016-06-24" @default.
- W2416946585 creator A5010872585 @default.
- W2416946585 creator A5025163442 @default.
- W2416946585 creator A5039923190 @default.
- W2416946585 creator A5040630645 @default.
- W2416946585 creator A5068977568 @default.
- W2416946585 creator A5075368397 @default.
- W2416946585 creator A5080896131 @default.
- W2416946585 date "1990-01-01" @default.
- W2416946585 modified "2023-09-26" @default.
- W2416946585 title "Phase II study of epirubicin in advanced soft tissue sarcoma." @default.
- W2416946585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2249019" @default.
- W2416946585 hasPublicationYear "1990" @default.
- W2416946585 type Work @default.
- W2416946585 sameAs 2416946585 @default.
- W2416946585 citedByCount "6" @default.
- W2416946585 crossrefType "journal-article" @default.
- W2416946585 hasAuthorship W2416946585A5010872585 @default.
- W2416946585 hasAuthorship W2416946585A5025163442 @default.
- W2416946585 hasAuthorship W2416946585A5039923190 @default.
- W2416946585 hasAuthorship W2416946585A5040630645 @default.
- W2416946585 hasAuthorship W2416946585A5068977568 @default.
- W2416946585 hasAuthorship W2416946585A5075368397 @default.
- W2416946585 hasAuthorship W2416946585A5080896131 @default.
- W2416946585 hasConcept C126322002 @default.
- W2416946585 hasConcept C136948725 @default.
- W2416946585 hasConcept C141071460 @default.
- W2416946585 hasConcept C142724271 @default.
- W2416946585 hasConcept C151032500 @default.
- W2416946585 hasConcept C2776694085 @default.
- W2416946585 hasConcept C2776755627 @default.
- W2416946585 hasConcept C2778256501 @default.
- W2416946585 hasConcept C2778629024 @default.
- W2416946585 hasConcept C2778822529 @default.
- W2416946585 hasConcept C2780580376 @default.
- W2416946585 hasConcept C2780835546 @default.
- W2416946585 hasConcept C29730261 @default.
- W2416946585 hasConcept C31760486 @default.
- W2416946585 hasConcept C71924100 @default.
- W2416946585 hasConcept C90924648 @default.
- W2416946585 hasConceptScore W2416946585C126322002 @default.
- W2416946585 hasConceptScore W2416946585C136948725 @default.
- W2416946585 hasConceptScore W2416946585C141071460 @default.
- W2416946585 hasConceptScore W2416946585C142724271 @default.
- W2416946585 hasConceptScore W2416946585C151032500 @default.
- W2416946585 hasConceptScore W2416946585C2776694085 @default.
- W2416946585 hasConceptScore W2416946585C2776755627 @default.
- W2416946585 hasConceptScore W2416946585C2778256501 @default.
- W2416946585 hasConceptScore W2416946585C2778629024 @default.
- W2416946585 hasConceptScore W2416946585C2778822529 @default.
- W2416946585 hasConceptScore W2416946585C2780580376 @default.
- W2416946585 hasConceptScore W2416946585C2780835546 @default.
- W2416946585 hasConceptScore W2416946585C29730261 @default.
- W2416946585 hasConceptScore W2416946585C31760486 @default.
- W2416946585 hasConceptScore W2416946585C71924100 @default.
- W2416946585 hasConceptScore W2416946585C90924648 @default.
- W2416946585 hasIssue "10" @default.
- W2416946585 hasLocation W24169465851 @default.
- W2416946585 hasOpenAccess W2416946585 @default.
- W2416946585 hasPrimaryLocation W24169465851 @default.
- W2416946585 hasRelatedWork W1901845528 @default.
- W2416946585 hasRelatedWork W1980701009 @default.
- W2416946585 hasRelatedWork W1981794048 @default.
- W2416946585 hasRelatedWork W2082065626 @default.
- W2416946585 hasRelatedWork W2083983329 @default.
- W2416946585 hasRelatedWork W2106688659 @default.
- W2416946585 hasRelatedWork W2224867602 @default.
- W2416946585 hasRelatedWork W2416946585 @default.
- W2416946585 hasRelatedWork W2791028417 @default.
- W2416946585 hasRelatedWork W3167433730 @default.
- W2416946585 hasVolume "77" @default.
- W2416946585 isParatext "false" @default.
- W2416946585 isRetracted "false" @default.
- W2416946585 magId "2416946585" @default.
- W2416946585 workType "article" @default.